{
    "clinical_study": {
        "@rank": "114276", 
        "acronym": "mentor\u21226", 
        "arm_group": {
            "arm_group_label": "rFXIII"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted globally. The aim of this observational study is to investigate the\n      incidence of specific adverse drug reactions associated with the use of recombinant factor\n      XIII (NovoThirteen\u00ae) in patients with congenital FXIII A-subunit deficiency (congenital\n      FXIII deficiency), comprising FXIII antibodies, allergic reactions, embolic and thrombotic\n      events and lack of therapeutic effect.\n\n      The study will aim at observing all patients exposed to NovoThirteen\u00ae in the EU, and\n      additional patients from selected non-EU countries. Recombinant FXIII (rFXIII) is registered\n      in EU and Switzerland as NovoThirteen\u00ae and in Canada as Tretten\u00ae."
        }, 
        "brief_title": "Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Congenital FXIII Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any study-related activities. (Study-related\n             activities are any procedure related to recording of data according to the protocol)\n\n          -  Able and willing to provide signed informed consent (or patient's legally acceptable\n             representative (LAR) consent, if applicable), as required by local ethics committee,\n             governmental or regulatory authorities\n\n          -  Congenital FXIII A-subunit deficiency\n\n          -  Actual or planned exposure to rFXIII"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This observational study will include patients with congenital FXIII A-subunit deficiency\n        for whom the decision to treat with rFXIII has been made and who are willing to provide\n        informed consent (or patient's legally acceptable representative (LAR) consent, if\n        applicable)."
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862367", 
            "org_study_id": "NN1841-3868", 
            "secondary_id": [
                "U1111-1131-1558", 
                "ENCEPP/SDPP/3687"
            ]
        }, 
        "intervention": {
            "arm_group_label": "rFXIII", 
            "description": "No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.", 
            "intervention_name": "catridecacog", 
            "intervention_type": "Drug", 
            "other_name": "recombinant factor XIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00c5rhus N", 
                        "country": "Denmark", 
                        "zip": "8200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Denmark", 
                "Spain"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Canada: Health Canada", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with rFXIII,comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of effect collected", 
            "safety_issue": "No", 
            "time_frame": "During study period up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862367"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "All serious adverse events collected", 
                "safety_issue": "No", 
                "time_frame": "During study period up to 5 years"
            }, 
            {
                "measure": "All medical events of special interest collected", 
                "safety_issue": "No", 
                "time_frame": "During study period up to 5 years"
            }, 
            {
                "measure": "All medication errors and near medication errors collected", 
                "safety_issue": "No", 
                "time_frame": "During study period up to 5 years"
            }, 
            {
                "measure": "Use of rFXIII in patients with congenital FXIII A-subunit deficiency also for other uses than for prophylactic treatment collected", 
                "safety_issue": "No", 
                "time_frame": "During study period up to 5 years"
            }, 
            {
                "measure": "Frequency of bleeding episodes collected", 
                "safety_issue": "No", 
                "time_frame": "During study period up to 5 years"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}